Clinical Trials Browser

Irinotecan × Thoracic × 1 year × Clear all

Carcinoma, Non-Small-Cell Lung, Colonic Neoplasms, Esophageal Neoplasms, Lung Neoplasms, Neoplasm Metastasis, Ovarian Neoplasms, Pancreatic Neoplasms, Rectal Neoplasms, Colorectal Neoplasms, Endometrial Neoplasms, Cholangiocarcinoma

NCT06586515 2026-04-20

MOONRAY-01

Phase 1 Recruiting

630 enrolled

GastrointestinalThoracic

Carcinoma, Non-Small-Cell Lung, Colorectal Neoplasms

NCT02595931 2026-04-13

M6620 and Irinotecan Hydrochloride in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery

Phase 1 Active not recruiting

66 enrolled

GastrointestinalThoracic

Lung Neoplasms, Neoplasm Metastasis, Pancreatic Neoplasms, Colorectal Neoplasms, Small Cell Lung Carcinoma

NCT03678883 2026-04-03

9-ING-41 in Patients With Advanced Cancers

Phase 2 Active not recruiting

350 enrolled

BreastCNSGastrointestinalGenitourinaryLymphoidOther hematologic neoplasmSarcomaThoracic

Bone Neoplasms, Breast Neoplasms, Glioma, Kidney Neoplasms, Lung Neoplasms, Lymphoma, Non-Hodgkin, Neoplasm Metastasis, Neoplasms, Hereditary Sensory and Autonomic Neuropathies, Pancreatic Neoplasms, Sarcoma, Colorectal Neoplasms, Leukemia-Lymphoma, Adult T-Cell

NCT05153239 2026-03-09

Clinical Trial of Lurbinectedin as Single-agent or in Combination With Irinotecan Versus Topotecan or Irinotecan in Patients With Relapsed Small-cell Lung Cancer (LAGOON)

Phase 3 Active not recruiting

705 enrolled

Thoracic

Small Cell Lung Carcinoma

NCT04640480 2026-01-27

Dose-finding Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of SNB-101(SN-38) in Patients With Tumors

Phase 1 Completed

21 enrolled

BreastGastrointestinalGynecologicHead & NeckThoracic

Breast Neoplasms, Head and Neck Neoplasms, Ovarian Neoplasms, Pancreatic Neoplasms, Stomach Neoplasms, Colorectal Neoplasms, Small Cell Lung Carcinoma

NCT07155200 2025-12-22

Small Cell Lung Cancer Irinotecan and CDC2-like Kinase Inhibition Trial (SLICK Trial)

Phase 1/2 Recruiting

42 enrolled

Thoracic

Small Cell Lung Carcinoma

NCT07258147 2025-12-02

Safety and Efficacy of Radiotherapy Combined With Immunochemotherapy in Pre-treated SCLC Patients With Liver Metastases

Phase 2 Not yet recruiting

30 enrolled

Thoracic

Lung Neoplasms

NCT02611024 2025-07-09

Pharmacokinetic Study of Lurbinectedin in Combination With Irinotecan in Patients With Selected Solid Tumors

Phase 1/2 Completed

316 enrolled

CNSEndocrineGastrointestinalGynecologicNETOther solid neoplasmSarcomaThoracic

Gastro-enteropancreatic neuroendocrine tumor, Carcinoma, Ovarian Epithelial, Glioblastoma, Mesothelioma, Neoplasms, Sarcoma, Stomach Neoplasms, Colorectal Neoplasms, Endometrial Neoplasms, Neuroendocrine Tumors

NCT06954246 2025-06-18

A Study of MHB088C Injection Versus Treatment of Physician's Choice in Subjects With Relapsed Small Cell Lung Cancer

Phase 3 Recruiting

450 enrolled

Thoracic

Small Cell Lung Carcinoma

NCT02419495 2025-06-04

Phase IB Study to Evaluate the Safety of Selinexor (KPT-330) in Combination With Multiple Standard Chemotherapy or Immunotherapy Agents in Patients With Advanced Malignancies

Phase 1 Terminated

221 enrolled

BreastDermatologicGenitourinaryGynecologicThoracic

Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Fallopian Tube Neoplasms, Lung Neoplasms, Melanoma, Neoplasm Metastasis, Ovarian Neoplasms, Triple Negative Breast Neoplasms

NCT06963502 2025-05-09

A Phase Ib Study of HS-10370 in Addition to Other Anti-cancer Therapies in Patients With Advanced Solid Tumors

Phase 1 Not yet recruiting

762 enrolled

GastrointestinalThoracic

Carcinoma, Non-Small-Cell Lung, Colorectal Neoplasms

Clinical Trials

A Study of the Pan-KRAS Inhibitor LY4066434 in Participants With KRAS Mutant Solid Tumors

MOONRAY-01

M6620 and Irinotecan Hydrochloride in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery

9-ING-41 in Patients With Advanced Cancers

Clinical Trial of Lurbinectedin as Single-agent or in Combination With Irinotecan Versus Topotecan or Irinotecan in Patients With Relapsed Small-cell Lung Cancer (LAGOON)

Dose-finding Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of SNB-101(SN-38) in Patients With Tumors

Small Cell Lung Cancer Irinotecan and CDC2-like Kinase Inhibition Trial (SLICK Trial)

Safety and Efficacy of Radiotherapy Combined With Immunochemotherapy in Pre-treated SCLC Patients With Liver Metastases

Pharmacokinetic Study of Lurbinectedin in Combination With Irinotecan in Patients With Selected Solid Tumors

A Study of MHB088C Injection Versus Treatment of Physician's Choice in Subjects With Relapsed Small Cell Lung Cancer

Phase IB Study to Evaluate the Safety of Selinexor (KPT-330) in Combination With Multiple Standard Chemotherapy or Immunotherapy Agents in Patients With Advanced Malignancies

A Phase Ib Study of HS-10370 in Addition to Other Anti-cancer Therapies in Patients With Advanced Solid Tumors